Intracerebral Hemorrhage
Conditions
Keywords
Brain hemorrhage, Cerebral Hemorrhage, Deferoxamine, Xingnaojing injection, Hematoma edema
Brief summary
The main purpose of this study is to determine whether deferoxamine and xingnaojing injection is effective and safe as a treatment for intracerebral hemorrhage.
Detailed description
Research shows that more than 1/3 of patients with acute cerebral hemorrhage in the first 24 hours will be expanding hematoma. The treatment of acute cerebral hemorrhage has two main targets: prevention of hematoma enlargement in primary brain damage; Reduce hematoma secondary brain damage caused by blood toxicity degradation products. At present, the curative effect of drug treatment of acute cerebral hemorrhage remains limited, using drug therapy to treat hematoma caused by blood toxicity degradation products secondary brain damage, is one of the main current international research direction and hotspot. Recent studies have found that iron overload in cells in acute cerebral hemorrhage stove weeks edema secondary lesion plays a very important role. Acute cerebral hemorrhage animal model research and small sample clinical study has shown that the iron chelator deferoxamine has good curative effect and security. Currently ongoing international HI-DEF test plans to assess the efficacy and safety of high-dose deferoxamine treatment within 24 h of patients with acute cerebral hemorrhage. Basic research shows Xingnaojing injection can inhibit inflammatory reaction, scavenging free radicals, relieve acute cerebral hemorrhage hematoma surrounding edema and has a variety of brain protection mechanism. The current study builds on these results to assess the potential utility of deferoxamine and Xingnaojing injection as a therapeutic intervention in ICH. This is a prospective, multi-center, double-blind, randomized, placebo-armed clinical study to test the safety and effectiveness of deferoxamine and Xingnaojing injection treatment in intracerebral hemorrhage. The investigators will randomize 180 subjects with ICH equally (1:1:1) to either DFO at 40mg/kg/day (up to a maximum daily dose of 6000 mg/day), or Xingnaojing injection, or saline placebo, given by continuous IV infusion for 5 consecutive days. Treatment will be initiated within 12 hours after ICH symptom onset. The main objectives are: 1. Examining the effects of DFO and Xingnaojing injection on peri-hematoma edema (PHE) volume progression between baseline and post-treatment CT/MRI scans and the residual cavity volume at 90 days. 2. Obtaining data on the National Institute of Health Stroke Scale (NIHSS) to explore the effects of treatment on neurological functions. 3. Examining the effects of DFO and Xingnaojing injection on biomarkers of acute cerebral hemorrhage such as ferritin, interleukin - 6, matrix metalloproteinase 9, tumor necrosis factor alpha and so on. 4. Study the traditional Chinese medicine(TCM)curative effect evaluation of the roles of different treatment methods on secondary damage after ICH. Secondary and exploratory objectives include: 1. Exploring whether the effect of DFO on outcome is dependent on initial ICH volume, after adjusting for other prognostic variables, to determine if specific limits for ICH volume should be specified as exclusion/inclusion criteria for future studies. 2. Exploring the differences between early (≤12h) and late (\>12-24h) OTT windows in DFO treatment effect on functional outcome. Exploratory study shows that iron chelator deferoxamine is effective and safe in the treatment of acute cerebral hemorrhage. We choose within 12 hours as the treatment time window, different from within 24 hours in the current international ongoing HI-DEF test. In theory, the earlier, the better curative effect. So this experiment is more likely to get a better curative effect. Xingnaojing injection is widely used in clinical in china, but lack of rigorous randomized controlled trial to prove its brain protection effect currently. Successful completion of this study will provide a crucial, reliable experimental evidence for a new treatment for acute cerebral hemorrhage. ICH is one of main causes of disability and death. A successful study demonstrating the efficacy of DFO and xingnaojing injection would be of considerable public health significance.
Interventions
DRUGdeferoxamine
Deferoxamine mesylate(40 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
Xingnaojing injection (20 ml/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
DRUGNormal saline
This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
Sponsors
Beijing Tiantan Hospital
Peking University First Hospital
People's Hospital of Beijing Daxing District
Beijing Haidian Hospital
The 263 Hospital of PLA
Beijing Aerospace General Hospital
Peking University Third Hospital
Beijing Pinggu District Hospital
Beijing Shuyi Hospital
General Hospital of Beijing PLA Military Region
Beijing Luhe Hospital
Beijing Fangshan District Liangxiang Hospital
Beijing Neurosurgical Institute
Beijing Jishuitan Hospital
Beijing Ditan Hospital
Beijing Youyi Hospital
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peking University People's Hospital
The Second Artillery General Hospital
Chinese PLA General Hospital
Capital Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 and ≤ 80 years 2. The diagnosis of ICH is confirmed by brain CT scan 3. NIHSS score ≥ 6 and GCS \> 6 upon presentation 4. The first dose of the study drug can be administered within 12h of ICH symptom onset 5. Functional independence prior to ICH, defined as pre-ICH mRS ≤ 1 6. Signed and dated informed consent is obtained.
Exclusion criteria
1. Known hypersensitivity to deferoxamine or xingnaojing injection 2. Known severe iron deficiency anemia (defined as hemoglobin concentration \< 7g/dL or requiring blood transfusions) 3. Abnormal renal function, defined as serum creatinine \> 2 mg/dL 4. Planned surgical evacuation of ICH prior to administration of study drug 5. Suspected secondary ICH related to tumour, ruptured aneurysm or arteriovenous malformation, hemorrhagic transformation of an ischemic infarct, or venous sinus thrombosis 6. Infratentorial hemorrhage 7. Irreversibly impaired brainstem function (bilateral fixed and dilated pupils and extensor motor posturing) 8. Complete unconsciousness, defined as a score of 3 on item 1a of the NIHSS (Responds only with reflex motor or autonomic effects or totally unresponsive, and flaccid) 9. Pre-existing disability, defined as pre-ICH mRS ≥ 2 10. Coagulopathy - defined as elevated aPTT or INR \>1.3 upon presentation; concurrent use of direct thrombin inhibitors (such as dabigatran), direct factor Xa inhibitors (such as rivaroxaban), or low-molecular-weight heparin 11. Taking iron supplements containing ≥ 325 mg of ferrous iron 12. Patients with heart failure taking \> 500 mg of vitamin C daily 13. Known severe hearing loss 14. Known pregnancy, or positive pregnancy test, or breastfeeding 15. Patients known or suspected of not being able to comply with the study protocol due to alcoholism, drug dependency, noncompliance, living in another state or any other cause 16. Life expectancy of less than 90 days due to comorbid conditions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Numbers of patients with the perihematomal edema (PHE) volume variation. | 7 days | decreases of more than 20% from initial PHE volumes were defined as decreased PHE volume; increases of more than 20% from initial PHE volumes were defined as increased PHE volume; changes between -20% and 20% were defined as unchanged. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The residual cavity volume | 90 days | the variation of residual cavity volume of |
| The variation of the mRS score and the Bathel Index | 90 days | the variation of mRS score and Bathel Index of different treated subjects from ICH onset to treatment time windows. |
| mortality | 90 days | the mortality of different treated subjects from ICH onset to treatment time windows. |
| Frequency of Treatment-related Adverse Events | 90 days | The safety endpoints will include all DFO-related adverse events until day-7 or discharge (whichever is earlier), and DFO-related SAEs and through day-90. |
Countries
China
Contacts
Primary ContactMaolin He, MD
Outcome results
None listed